Extended-Release Drugs Market Report 2026

Extended-Release Drugs Market Overview

• Extended-Release Drugs market size has reached to $69.63 billion in 2025 • Expected to grow to $126.89 billion in 2030 at a compound annual growth rate (CAGR) of 13% • Growth Driver: Rising Chronic Conditions Is A Catalyst For Growth In The Extended-Release Drug Market • Market Trend: Extended-Release Tablets For Enhanced Treatment Of Huntington Disease-Related Movement Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Extended-Release Drugs Market?

Extended-release drugs are a dosage form made to release the medication over a longer time, at a predetermined rate, duration, and location, in a controlled manner. The drug can be taken less frequently than the immediate release form, and patients may take 1 to 2 doses each day instead of 3 to 4. The main types of extended-release drugs are sustained-release drugs and controlled-release drugs. Sustained release drug refers to medication that is intended to slowly release in the body over time, primarily to maintain therapeutic levels. They are available as over-the-counter and prescription modes and distributed by hospital pharmacies, retail pharmacies, mail-order pharmacies, and drug store channels.

What Is The Extended-Release Drugs Market Growth Forecast?

The extended-release drugs market size is expected to see rapid growth in the next few years. It will grow to $126.89 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to growth of precision medicine, increasing adoption of oral controlled-release formulations, expansion of hospital and retail pharmacies, rising geriatric population, investment in novel delivery technologies. Major trends in the forecast period include personalized dosage regimens, advanced drug delivery systems, patient adherence optimization, novel formulation technologies, extended-release combination therapies.

Global Extended-Release Drugs Market Segmentation

1) By Type: Sustained Release Drug, Controlled Release Drug 2) By Mode: Over-The-Counter, Prescription 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores Subsegments: 1) By Sustained Release Drug: Matrix Systems, Coating Systems 2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

What Is The Driver Of The Extended-Release Drugs Market?

The increasing incidence of chronic conditions is expected to propel the growth of the extended-release drug market going forward. Chronic conditions are defined as conditions that last for a year or longer and necessitate continuing medical care, restricting everyday activities, or both. Heart disease, cancer, obesity, and diabetes are a few examples. Extended-release drug delivery systems are designed to provide a relatively constant level of medication in the body over a long period. It helps maintain a consistent therapeutic effect and avoids the fluctuations in drug levels that can occur with immediate-release medications. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Therefore, the increasing incidence of chronic conditions is driving the growth of the extended-release drug industry.

Key Players In The Global Extended-Release Drugs Market

Major companies operating in the extended-release drugs market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Watson Pharmaceuticals Inc.

Global Extended-Release Drugs Market Trends and Insights

Major companies operating in the extended-release drugs market are developing innovative products such as next-generation extended-release tablets to enhance product offerings and gain a competitive advantage. Extended-release tablets are a type of pharmaceutical formulation designed to release their active ingredients gradually over an extended period. For instance, in February 2023, Teva Pharmaceutical Industries Ltd. an Israel-based pharmaceutical company received approval from the U.S. Food and Drug Administration (FDA) for austedo XR (deutetrabenazine). Austedo XR is recommended for the treatment of adults with chorea and tardive dyskinesia related to Huntington disease. They come in dosages of 6, 12, and 24 mg. With the approval of austedo XR, patients with tardive dyskinesia and Huntington disease chorea now have another efficient treatment option. This allows individuals to live with these disorders and the medication is administered once daily. The development of austedo XR, which provides a practical and efficient therapeutic alternative for those with certain movement disorders, signifies a significant leap in the management of these ailments.

What Are Latest Mergers And Acquisitions In The Extended-Release Drugs Market?

In April 2024, ProMed Pharma, a US-based provider of polymer-based drug-releasing dosage forms and combination device components, acquired SpineThera’s manufacturing operational assets for an undisclosed amount. With this acquisition, ProMed Pharma aims to expand its technological capabilities in sustained- and extended-release drug formulation by integrating SpineThera’s biodegradable microsphere manufacturing platform. SpineThera is a US-based clinical-stage pharmaceutical company developing novel extended-release injectable therapies using its proprietary micro-suspension technology.

Regional Insights

North America was the largest region in the extended-release drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Extended-Release Drugs Market?

The extended-release drug market consists of sales of extended-release tablets, extended-release capsules, and implants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Extended-Release Drugs Market Report 2026?

The extended-release drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the extended-release drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.